Drug Development · us
One RNA Drug Lowers Two Blood Lipids: First Human Data Emerge for Dual-Target Therapy
In an early trial involving 31 people, ARO-DIMER-PA lowered both LDL cholesterol and triglycerides, providing preliminary evidence for simplifying the treatment of mixed hyperlipidemia; whether it can be used safely over the long term and reduce cardiovascular events remains to be verified.
When low-density lipoprotein cholesterol (LDL-C) and triglycerides are both elevated, treatment often needs to address different metabolic pathways. The first human data released by Cleveland Clinic suggest that ARO-DIMER-PA, an experimental RNA drug developed by Arrowhead, may lower both lipid measures with a single molecule. However, this advance currently represents an early lipid-lowering effect and has not yet been shown to reduce heart attacks or strokes.
The results come from the single ascending-dose portion of a Phase 1/2a trial, presented by investigator Luke Laffin on November 7 at the American Heart Association Scientific Sessions in Chicago. The randomized, double-blind, placebo-controlled trial enrolled 31 adults with mixed hyperlipidemia who received either placebo or one of five drug doses ranging from 25 to 400 milligrams.
ARO-DIMER-PA is a small interfering RNA (siRNA) drug that uses RNA interference to suppress the liver’s production of two proteins, PCSK9 and APOC3. The former promotes the breakdown of LDL receptors, while the latter impedes the breakdown and clearance of triglyceride-rich lipoproteins. Suppressing both may allow the liver to process different types of blood lipids more effectively.
Across the doses evaluated, mean PCSK9 and APOC3 concentrations fell by 50% to 89% and 43% to 95% from baseline, respectively; mean LDL-C fell by 26% to 65%, and median triglycerides fell by 56% to 78%. These are reductions from pretreatment levels at different doses. They should not be interpreted as indicating that every participant achieved the same effect, nor are they differences adjusted for changes in the placebo group.
Regarding safety, no serious adverse events were reported in the study, but injection-site redness was quite common. The clinic’s professional report noted that 95% of those receiving the drug experienced this reaction; its newsroom separately noted more side effects in the highest-dose group, which received 400 milligrams. Data from such a small study involving a single dose remain insufficient to rule out rare risks or risks associated with cumulative dosing.
The next key questions are whether the effect can be maintained with repeated dosing and how often injections will be needed. Multiple ascending-dose evaluation is ongoing and will help guide dose selection for subsequent trials. Even with substantial lipid reductions, the optimal dosing interval, long-term safety, and cardiovascular benefits still require answers from further studies.
The study was funded by Arrowhead. According to Cleveland Clinic’s disclosures, Laffin serves on Arrowhead’s trial steering committee, with the associated compensation paid to the clinic’s academic research organization, C5Research. Both currently available public reports were issued by the clinic participating in the research and provide early trial signals; interpretation should remain within the scope of this evidence.